Results 71 to 80 of about 4,529 (167)

Nebivolol in the treatment of chronic heart failure

Vascular Health and Risk Management, 2007
Angie Veverka, Jennifer L SalinasWingate University School of Pharmacy, Wingate, NC, USAAbstract: Nebivolol is a highly selective beta1-adrenergic blocker that also enhances nitric oxide bioavailability via the L-arginine-nitric oxide pathway, leading to
Angie Veverka, Jennifer L Salinas
doaj  

Comparison of the safety and efficacy of ivabradine and nebivolol mono- and combination therapies in the treatment of stable angina pectoris patients with left ventricular dysfunction

Bangladesh Journal of Pharmacology, 2013
We aimed to investigate the pharmacoeconomic efficacy of ivabradine and nebivolol in treatment of stable angina pectoris patients with left ventricular dysfunction prospectively. Pharmacoeconomic analysis was performed by using cost minimization analysis,
Rasim Kutlu, Mehmet Erdem Memetoglu, Tolkun Murataliev Muratalievic   +2 more
doaj  

Nebivolol [PDF]

, 2020
openaire   +1 more source

Rational pharmacotherapy of chronic heart failure with increased endothelin-1 activity: beta-adrenoblocker nebivolol place

Кардиоваскулярная терапия и профилактика, 2007
Aim. To optimize chronic heart failure (CHF) pharmacotherapy, basing on endothelin (ET) system activity, functional and cardio-hemodynamic parameters, and their dynamics in beta-adrenoblocker nebivolol therapy. Material and methods. The study included 52
L. I. Olbinskaya, Yu. I. Naymann
doaj  

Effect of nebivolol on nitric oxide availability and ADMA concentration in CAD patients after PCI: Prospective randomized double-blind study. [PDF]

Qatar Med J
Aldallal AAR, Razzaq MA, Hameed AMA, Merza HJ, Hasan HK, Mohammed SJ.   +5 more
europepmc   +1 more source

Long-term clinical outcomes of carvedilol versus nebivolol in patients with ST-segment elevation myocardial infarction treated with second-generation drug-eluting stents: insights from a Korean nationwide multicenter prospective registry. [PDF]

Front Cardiovasc Med
Ahn J, Yu HY, Rha SW, Choi SY, Byun JK, Park S, Choi CU, Ahn Y, Jin D, Choi BG.   +9 more
europepmc   +1 more source

Nebivolol treatment improves hypertension-induced endothelial cell dysfunction by reducing TGF-β1-dependent senescence and normalizing mitochondrial indices. [PDF]

J Hypertens
Uruski P, Mikuła-Pietrasik J, Tykarski A, Książek K.   +3 more
europepmc   +1 more source

Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways. [PDF]

Front Pharmacol
Al-Mahdawi MA, Fawzi HA, Ibrahim N, Muhammad N.   +3 more
europepmc   +1 more source

Nebivolol Protects the Thoracic and Abdominal Aorta and Their Perivascular Adipose Tissue From the Differential Detrimental Effects of Obesity. [PDF]

Fundam Clin Pharmacol
Dourado TMH, Pimenta GF, Silva LP, Assis VO, Silva AO, Tirapelli CR.   +5 more
europepmc   +1 more source

Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study. [PDF]

Sci Rep
Tarek M, Ali AA, Biomy R, Abdelkawy K, El-Khateeb E.   +4 more
europepmc   +1 more source